ATE326223T1 - Methode zur behandlung der hyperaktiven blase - Google Patents
Methode zur behandlung der hyperaktiven blaseInfo
- Publication number
- ATE326223T1 ATE326223T1 AT01941430T AT01941430T ATE326223T1 AT E326223 T1 ATE326223 T1 AT E326223T1 AT 01941430 T AT01941430 T AT 01941430T AT 01941430 T AT01941430 T AT 01941430T AT E326223 T1 ATE326223 T1 AT E326223T1
- Authority
- AT
- Austria
- Prior art keywords
- hyperactive bladder
- compound
- methods
- treating hyperactive
- treating
- Prior art date
Links
- 206010020853 Hypertonic bladder Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- SCMPVSAUZONHCN-JOCHJYFZSA-N n-[(2s)-2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-n-methylbenzamide Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1N1CCCNC1=O SCMPVSAUZONHCN-JOCHJYFZSA-N 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015246.2A GB0015246D0 (en) | 2000-06-22 | 2000-06-22 | Method for the treatment of urinary incontinence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326223T1 true ATE326223T1 (de) | 2006-06-15 |
Family
ID=9894138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01941430T ATE326223T1 (de) | 2000-06-22 | 2001-06-20 | Methode zur behandlung der hyperaktiven blase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030139433A1 (de) |
| EP (1) | EP1307202B1 (de) |
| JP (1) | JP2003535901A (de) |
| AT (1) | ATE326223T1 (de) |
| AU (1) | AU2001274786A1 (de) |
| DE (1) | DE60119742T2 (de) |
| ES (1) | ES2262654T3 (de) |
| GB (1) | GB0015246D0 (de) |
| WO (1) | WO2001097811A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1330257B1 (de) * | 2000-10-30 | 2005-08-31 | University Of Zurich | Verwendung von gnrh-analogue zur behandlung der harninkontinenz |
| SE0103668D0 (sv) * | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Method for the treatment of overactive blader |
| SE0103795D0 (sv) * | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| CA2543552A1 (en) * | 2003-10-27 | 2005-05-06 | Novartis Ag | Use of neurokinin antagonists in the treatment of urinary incontinence |
| WO2006121389A1 (en) * | 2005-05-10 | 2006-11-16 | Astrazeneca Ab | Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity |
| EP4410295A3 (de) * | 2017-06-06 | 2024-10-16 | Urovant Sciences GmbH | Verwendung von vibegron zur behandlung der hyperaktiven blase |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317104D0 (en) * | 1993-08-17 | 1993-09-29 | Zeneca Ltd | Therapeutic heterocycles |
| GB9322643D0 (en) * | 1993-11-03 | 1993-12-22 | Zeneca Ltd | Lactam derivatives |
| US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
| GB9505084D0 (en) * | 1995-03-14 | 1995-05-03 | Pfizer Ltd | Benzamide derivative |
| CN1309638A (zh) * | 1998-07-10 | 2001-08-22 | 阿斯特拉曾尼卡有限公司 | 作为神经激肽受体拮抗剂的n－取代的萘甲酰胺 |
| GB9922519D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9924141D0 (en) * | 1998-10-30 | 1999-12-15 | Zeneca Ltd | Treatment of gastric asthma |
| GB9826941D0 (en) * | 1998-12-09 | 1999-02-03 | Zeneca Pharmaceuticals | Compounds |
-
2000
- 2000-06-22 GB GBGB0015246.2A patent/GB0015246D0/en not_active Ceased
-
2001
- 2001-06-20 US US10/311,700 patent/US20030139433A1/en not_active Abandoned
- 2001-06-20 AT AT01941430T patent/ATE326223T1/de not_active IP Right Cessation
- 2001-06-20 EP EP01941430A patent/EP1307202B1/de not_active Expired - Lifetime
- 2001-06-20 DE DE60119742T patent/DE60119742T2/de not_active Expired - Fee Related
- 2001-06-20 WO PCT/SE2001/001420 patent/WO2001097811A1/en not_active Ceased
- 2001-06-20 JP JP2002503295A patent/JP2003535901A/ja active Pending
- 2001-06-20 AU AU2001274786A patent/AU2001274786A1/en not_active Abandoned
- 2001-06-20 ES ES01941430T patent/ES2262654T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2262654T3 (es) | 2006-12-01 |
| WO2001097811A1 (en) | 2001-12-27 |
| EP1307202A1 (de) | 2003-05-07 |
| US20030139433A1 (en) | 2003-07-24 |
| EP1307202B1 (de) | 2006-05-17 |
| JP2003535901A (ja) | 2003-12-02 |
| DE60119742T2 (de) | 2007-05-31 |
| DE60119742D1 (de) | 2006-06-22 |
| AU2001274786A1 (en) | 2002-01-02 |
| GB0015246D0 (en) | 2000-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60134874D1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
| CY1110742T1 (el) | Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης | |
| DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
| ATE224884T1 (de) | Muscarin-antagonisten | |
| DE60127537D1 (de) | VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE | |
| MXPA05007771A (es) | Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno. | |
| DE60119742D1 (de) | Methode zur behandlung der hyperaktiven blase | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE390134T1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| BR0213832A (pt) | Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma | |
| DE60117541D1 (de) | Candesartan zur Behandlung von Migräne | |
| ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
| SE0100873D0 (sv) | Method of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |